Immunotherapy combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT03095352
First seen Jan 08, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (carboplatin) helps control breast cancer that has returned on the chest wall. The trial included 76 women with either triple-negative or hormone-resistant breast cancer. Researchers measured how many patients had their disease shrink or stay stable after 18 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.